WASHINGTON–(BUSINESS WIRE)–Researchers have harnessed the human eye’s ability to detect subtle color differences and identify ‘thin films’ that differ in thickness by a few nanometers, about the width of a single virus.
Author: Business Wire
Presbia Reaches the Halfway Mark in Second Stage Enrollment in the US FDA Pivotal Study
DUBLIN–(BUSINESS WIRE)–Presbia PLC (NASDAQ: LENS), an ophthalmic device company that has developed and is currently marketing the Presbia Flexivue Microlens™, a revolutionary optical lens implant for treating presbyopia today announced that it has treated over 50% of subjects in the second stage enrollment of its pivotal study. Presbia received FDA approval to commence the second stage of its pivotal study in February, and continues enrollment of subjects at eleven investigational sites acros
Tyrogenex Presents Phase 1 Study of X-82 for Wet AMD at the International Symposium on Ocular Pharmacology and Therapeutics Clinical
NEEDHAM, Mass. & PALM BEACH GARDENS, Fla.–(BUSINESS WIRE)–Tyrogenex, a privately held company focused on the development of next-generation targeted therapeutics for cancer and ophthalmology, announced data from its phase 1 safety study of X-82 at ISOPT.
Clearside Biomedical, Inc. to Present at International Symposium on Ocular Pharmacology and Therapeutics (ISOPT) Clinical Meeting
ALPHARETTA, Ga.–(BUSINESS WIRE)–Clearside Biomedical, which develops drug therapies to treat eye diseases, to present July 10 at the International Symposium on Ocular Pharmacology and Therapeutics (ISOPT) Clinical meeting in Berlin.
Vital Art and Science Announces a New US Patent for its mVT® Service for Age Related Macular Degeneration and Diabetic Retinopathy Patients
DALLAS–(BUSINESS WIRE)–Vital Art and Science, LLC (VAS) announced today that the US Patent Office has granted another patent covering the novel technology of the firm’s innovative new mVT Service. The mVT Service is a FDA-cleared prescription medical device that conveniently and accurately tracks changes caused by AMD and DR. Use of the device enables clinicians to catch disease progression early when it is most responsive to treatment. VAS continues to validate the uniqueness of its advanced
Research and Markets: North America Ophthalmology Cataract Surgery Devices Market by Sub-Market & End-Users – Analysis and Forecast to 2019
DUBLIN–(BUSINESS WIRE)–Research and Markets (http://www.researchandmarkets.com/research/gbr5bg/north_america) has announced the addition of the “North America Ophthalmology Cataract Surgery Devices Market by Sub-Market (Intraocular Lenses, Phacoemuls…
pSivida Announces Top-Line Results from Investigator-Sponsored Phase II Study of Medidur™ for Uveitis to Be Reported Next Week
WATERTOWN, Mass.–(BUSINESS WIRE)–pSivida announces top-line results from investigator-sponsored phase II study of Medidur for uveitis to be reported next week at ASRS Meeting in Vienna
GenSight Biologics nomme Thomas Gidoin comme Directeur Financier et Michael Wyzga au Conseil d’Administration
PARIS–(BUSINESS WIRE)–GenSight Biologics SA (GenSight), société biopharmaceutique dédiée à la découverte et au développement de thérapies géniques innovantes pour le traitement des maladies mitochondriales et neurodégénératives de l’œil, et à l’avenir, du système nerveux central, a annoncé les nominations de Thomas Gidoin comme Directeur Financier et Michael Wyzga comme Administrateur Indépendant. Dans ce rôle, M. Gidoin sera responsable du développement des opérations financières et de la st
GenSight Biologics Appoints Thomas Gidoin as Chief Financial Officer & Michael Wyzga to Board of Directors
PARIS–(BUSINESS WIRE)–GenSight Biologics S.A. (GenSight), a clinical-stage biotechnology company discovering and developing novel therapies for mitochondrial and neurodegenerative diseases of the eye, and in the future, of the central nervous system, announced the appointments of Thomas Gidoin as Chief Financial Officer and Michael Wyzga as Independent Director. In this role, Mr. Gidoin is responsible for the company’s corporate and financial development strategies and operations, and will re
India’s Refractive Surgery Society Awards Special Gold Medal to LENSAR CEO Nicholas T. Curtis
ORLANDO, Fla. & CHENNAI, India–(BUSINESS WIRE)–The Intraocular Implant and Refractive Society of India (IIRSI) awarded a Special Gold Medal to Nicholas T. Curtis, CEO of LENSAR, Inc., a global leader in next generation femtosecond laser technology for refractive cataract surgery, for his outstanding contribution to industry. The award was presented in Chennai at the IIRSI Conference by Dr. C. Vijaya Bhaskar, honorable Minister for Health, Medical Education and Family Welfare for the state of
LENSAR Expands Presence in India; Sharp Sight Centres Choose the LENSAR Laser System
ORLANDO, Fla. & DELHI, India–(BUSINESS WIRE)–Dr. Kamal Kapur Chooses LENSAR’s Advanced Femtosecond Cataract Platform To Launch Laser-Assisted Cataract Procedure Practice at Sharp Sight Centres in Delhi, India
Acucela Hires Roger Girard as Chief Strategy Officer
SEATTLE–(BUSINESS WIRE)–Acucela Inc. (TOKYO: 4589) (“Acucela” or the “Company”), a clinical-stage biotechnology company that specializes in discovering and developing novel drug candidates to potentially treat and slow the progression of sight-threatening ophthalmic diseases, announced today that it has hired Roger Girard as Chief Strategy Officer. Having built 14 successful companies over the past 40 years in multiple industries, Girard brings deep experience in business management and will
Research and Markets: Retinitis Pigmentosa (Retinitis) – Active Pharmaceutical Ingredients Insights 2015-2016
DUBLIN–(BUSINESS WIRE)–Research and Markets (http://www.researchandmarkets.com/research/5rfx92/retinitis) has announced the addition of the “Retinitis Pigmentosa (Retinitis)-API Insights” report to their offering. Retinitis Pigmentosa (Retinitis)-API…
Research and Markets: Gene Therapy Ophthalmology Insight: Pipeline Assessment, Market Trend, Technology and Competitive Landscape
DUBLIN–(BUSINESS WIRE)–Research and Markets (http://www.researchandmarkets.com/research/wzsmx2/gene_therapy) has announced the addition of the “Gene Therapy Ophthalmology Insight: Pipeline Assessment, Market Trend, Technology and Competitive Landscap…
Ocata Therapeutics to Present at the Cantor Fitzgerald Inaugural Healthcare Conference
MARLBOROUGH, Mass.–(BUSINESS WIRE)–Ocata Therapeutics, Inc. (“Ocata” or “the Company”; NASDAQ: OCAT), a leader in the field of Regenerative Ophthalmology™, today announced that Paul Wotton, Ph.D., President and Chief Executive Officer, will present a company overview at the Cantor Fitzgerald Inaugural Healthcare Conference on Wednesday, July 8, 2015 at 11:15 a.m. EDT at the Le Parker Meridien Hotel, New York City. A live audio webcast of the presentation will be available via the “Investor Re
Aerie Pharmaceuticals to Present at the Cantor Fitzgerald 2015 Healthcare Conference
IRVINE, Calif. & BEDMINSTER, N.J. & RESEARCH TRIANGLE PARK, N.C.–(BUSINESS WIRE)–Aerie Pharmaceuticals, Inc. (Nasdaq: AERI) today announced that Vicente Anido, Jr., Ph.D., Chief Executive Officer and Chairman of the Board, will present at the Cantor Fitzgerald Inaugural “From Bench to Bedside” Healthcare Conference on Wednesday, July 8, 2015 at 8:30a.m. ET in New York, NY. Dr. Anido’s presentation will include an Aerie overview and business update. Dr. Anido will also participate in the “Emer
Glaukos Corporation Announces Closing of Its Initial Public Offering
LAGUNA HILLS, Calif.–(BUSINESS WIRE)–Glaukos Corporation Announces Closing of Its Initial Public Offering.
Santa Clara Valley Blind Center Responds to Protestor Allegations, Reiterates “Vision Beyond Sight” Mission
SAN JOSE, Calif.–(BUSINESS WIRE)–The Santa Clara Valley Blind Center (SCVBC) officially responds to protest allegations by citing legal precedent and how it took action to protect its Mission.
Ocular Therapeutix™ to Participate at the Cantor Fitzgerald Inaugural Healthcare Conference
BEDFORD, Mass.–(BUSINESS WIRE)–Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the development and commercialization of innovative therapies for diseases and conditions of the eye, today announced that Brad Smith, Chief…
Research and Markets: Global Rhino-Conjunctivitis Therapeutics Pipeline Report 2015
DUBLIN–(BUSINESS WIRE)–Research and Markets (http://www.researchandmarkets.com/research/s4x5vx/rhinoconjunctivit) has announced the addition of the “Rhino-Conjunctivitis-Pipeline Insights” report to their offering. Rhino-Conjunctivitis Pipeline Insig…